Optimizing primary chemotherapy in ovarian cancer
- 1 August 2003
- journal article
- review article
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 17 (4) , 957-968
- https://doi.org/10.1016/s0889-8588(03)00058-3
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trialsBritish Journal of Cancer, 1998
- Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group.Journal of Clinical Oncology, 1998
- A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinomaAnnals of Oncology, 1997
- Cancer of the OvaryNew England Journal of Medicine, 1993
- A Prospective Randomized Comparison of 6 and 12 Cycles of Cyclophosphamide, Adriamycin, and Cisplatin in Advanced Epithelial Ovarian Cancer: A Danish Ovarian Study Group Trial (DACOVA)Gynecologic Oncology, 1993
- The impact of received dose intensity on the outcome of advanced ovarian cancerEuropean Journal Of Cancer, 1993
- Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinomaGynecologic Oncology, 1992
- Chemotherapy for advanced or recurrent gynecologic cancerCancer, 1987
- Epithelial Carcinoma of the Ovary: Current StrategiesAnnals of Internal Medicine, 1981
- Advanced Ovarian AdenocarcinomaNew England Journal of Medicine, 1978